Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/01/2023* 16:30 EST Earnings Call Q4 2022 -- -- --
03/01/2023* -- Results Q4 2022 -- -0.30 --
11/07/2022 16:30 EST Earnings Call Q3 2022 -- -- --
11/07/2022 -- Results Q3 2022 -0.43 -0.45 3.72%
08/08/2022 16:30 EST Earnings Call Q2 2022 -- -- --
08/08/2022 -- Results Q2 2022 -0.08 -0.24 66.91%
05/09/2022 16:30 EST Earnings Call Q1 2022 -- -- --
05/09/2022 -- Results Q1 2022 -0.52 -0.51 -1.18%
*Estimated Date/Time

Earnings

Next Report Date 03/01/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/07/2022
Beat/Miss Upgrade
Return Since 36.72%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
URL https://www.caratherapeutics.com
Investor Relations URL https://ir.caratherapeutics.com/
HQ State/Province Connecticut
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 01, 2023 (est.)
Last Earnings Release Nov. 07, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
69.11%
-44.90%
31.75%
6.21%
23.92%
-6.08%
-19.50%
4.84%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.26%
33.48%
-21.45%
63.03%
-40.72%
-6.96%
63.55%
-24.29%
-68.55%
--
-85.15%
37.29%
-56.05%
-78.69%
84.55%
-22.23%
-44.55%
--
54.82%
-19.69%
-76.28%
103.4%
-45.36%
-12.73%
-79.31%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-84.33%
As of December 02, 2022.

Profile

Edit
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
URL https://www.caratherapeutics.com
Investor Relations URL https://ir.caratherapeutics.com/
HQ State/Province Connecticut
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 01, 2023 (est.)
Last Earnings Release Nov. 07, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
CNBS 1.933M USD 4.50%
MJJ 331804.0 USD 0.68%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter CARA Tweets